ACTRN12621000208808
Recruiting
Phase 2
Effect of SGLT2 Inhibition With Empagliflozin on Atrial Fibrillation Severity in overweight adults (SWEET-AF)
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Atrial Fibrillation
- Sponsor
- The University of Adelaide
- Enrollment
- 300
- Status
- Recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •At least 18 years of age
- •Symptomatic paroxysmal or persistent AF (in sinus rhythm at time of enrolment)
- •Body mass index (BMI) \> 27
- •NB: A history of diabetes is not required for inclusion
Exclusion Criteria
- •Current or prior use of SGLT2 inhibitor
- •Not on stable glucose\-lowering regimen for 12 weeks if diabetic
- •Estimated glomerular filtration rate \< 30ml/min/1\.73m2
- •Acute, decompensated heart failure
- •Women pregnant, nursing, or who plan to become pregnant during trial period
- •Contraindication to CMR (implanted cardiac devices, cochlear implants, intracranial metallic implants and claustrophobia).
- •Inability to provide informed consent
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not Yet Recruiting
Phase 3
Impact of empagliflozin on nephrolithiasis among patients without diabetes compared to a placebo in reduction in the number and/or size of renal stonesephrolithiasisSLCTR/2023/012Professorial Medical Unit
Active, Not Recruiting
Phase 1
Empagliflozin reduces progression of diabetic retinopathy in patients with high risk of diabetic macular edemaEUCTR2016-000825-38-DEHannover Medical School80
Active, Not Recruiting
Phase 1
SGLT2 inhibition with empagliflozin in patients with type 2 diabetes mellitus: Influences on left ventricular mass, function, and lipid content of myocardium (EMPATROPHY)Patients with type 2 diabetes mellitus on background metformin treatment.MedDRA version: 18.0Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]EUCTR2014-003313-28-DEHannover Medical School60
Active, Not Recruiting
Phase 1
To investigate whether treatment with the SGLT-2 inhibitor dapagliflozin improves the perception of hypoglycemia in people with type 1 diabetes with impaired awareness of hypoglycemiaType 1 diabetesTherapeutic area: Diseases [C] - Hormonal diseases [C19]EUCTR2018-001569-17-NLRadboud university medical center15
Completed
Phase 2
Effect of the SGLT-2 inhibitor dapagliflozine on impaired awareness of hypoglycemia in type 1 diabetesDiabetesImpaired Awareness of Hypoglycemiahypoglycemia unawareness10018424NL-OMON48616Radboud Universitair Medisch Centrum15